(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 8.20%
@ $47.59
Utstedt: 3 mai 2024 @ 18:57
Avkastning: -0.27%
Forrige signal: mai 2 - 21:54
Forrige signal:
Avkastning: 0.06 %
Live Chart Being Loaded With Signals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases...
Stats | |
---|---|
Dagens volum | 1.10M |
Gjennomsnittsvolum | 1.42M |
Markedsverdi | 5.72B |
EPS | $0 ( 2024-05-02 ) |
Neste inntjeningsdato | ( $-0.550 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.67 |
ATR14 | $1.540 (3.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Sullivan Timothy Eugene | Sell | 14 164 | Common Stock |
2024-04-18 | Sullivan Timothy Eugene | Buy | 14 164 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Buy | 1 500 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Sell | 1 500 | Stock Option (Right to Buy) |
2024-04-08 | Deschatelets Pascal | Buy | 69 107 | Common Stock |
INSIDER POWER |
---|
2.39 |
Last 100 transactions |
Buy: 1 047 810 | Sell: 959 444 |
Volum Korrelasjon
Apellis Pharmaceuticals Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BRIVU | 0.949 |
MSDAU | 0.948 |
TIOAU | 0.945 |
VLAT | 0.945 |
INZY | 0.945 |
NVCN | 0.945 |
LDHA | 0.943 |
ALXN | 0.941 |
GVCI | 0.941 |
TIOA | 0.94 |
10 Mest negative korrelasjoner | |
---|---|
NDRA | -0.967 |
MNPR | -0.95 |
DFFN | -0.948 |
ENLV | -0.947 |
LSAQ | -0.945 |
MMAT | -0.945 |
JG | -0.942 |
ATNF | -0.942 |
MAGS | -0.941 |
ASRV | -0.938 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Apellis Pharmaceuticals Korrelasjon - Valuta/Råvare
Apellis Pharmaceuticals Økonomi
Annual | 2023 |
Omsetning: | $396.59M |
Bruttogevinst: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2023 |
Omsetning: | $396.59M |
Bruttogevinst: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2022 |
Omsetning: | $75.42M |
Bruttogevinst: | $69.79M (92.53 %) |
EPS: | $-6.15 |
FY | 2021 |
Omsetning: | $66.56M |
Bruttogevinst: | $61.36M (92.19 %) |
EPS: | $-8.84 |
Financial Reports:
No articles found.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.